Journal article
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
- Abstract:
-
Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascular outcomes and clinical safety. TECOS is a pragmatic, academically run, multinational, randomized, double-blind, placebo-controlled, event-driven trial recruiting approximately 14,000 patients in 38 countries who have type 2 diabetes (T2DM)...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- American heart journal
- Volume:
- 166
- Issue:
- 6
- Pages:
- 983-989.e7
- Publication date:
- 2013-12-01
- DOI:
- EISSN:
-
1097-6744
- ISSN:
-
0002-8703
- Source identifiers:
-
439526
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:439526
- UUID:
-
uuid:40047ae7-93e5-4cfc-b294-4b96bffc0277
- Local pid:
- pubs:439526
- Deposit date:
- 2014-08-21
Terms of use
- Copyright date:
- 2013
If you are the owner of this record, you can report an update to it here: Report update to this record